An open-label trial of the efficacy of 15% aluminum chloride in 2% salicylic acid gel base in the treatment of moderate-to-severe primary axillary hyperhidrosis

J Drugs Dermatol. 2009 May;8(5):477-80.

Abstract

Primary focal hyperhidrosis (HH) is a chronic disorder of excessive sweating. A single-center, open-label study was performed to determine the efficacy and safety of 15% aluminum chloride (AC) in 2% salicylic acid gel base (SAGB) Hydrosal in adults with moderate-to-severe primary axillary HH. Thirty subjects were given 15% AC in 2% SAGB to apply to their bilateral axillae nightly for the first week, then twice-weekly application as tolerated. The primary objective was change in mean Hyperhidrosis Disease Severity Score (HDSS) score from baseline to week 4. Participants who achieved an HDSS score < 2 were designated as "responders." Mean change in HDSS from baseline to week 4 was 1.32 (p = 0.0001). At week 4, 21 of 29 (72%) were responders, and at week 12, 18 of 25 (72%) were responders. Based on these results, 15% AC in 2% SAGB may be an effective, high-strength AC topical therapy for treatment of patients with moderate-to-severe axillary HH.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Adult
  • Aluminum Chloride
  • Aluminum Compounds / administration & dosage
  • Aluminum Compounds / adverse effects
  • Aluminum Compounds / therapeutic use*
  • Astringents / administration & dosage
  • Astringents / adverse effects
  • Astringents / therapeutic use*
  • Axilla
  • Chlorides / administration & dosage
  • Chlorides / adverse effects
  • Chlorides / therapeutic use*
  • Female
  • Gels
  • Humans
  • Hyperhidrosis / drug therapy*
  • Male
  • Pilot Projects
  • Salicylic Acid*
  • Sweating / drug effects
  • Treatment Outcome

Substances

  • Aluminum Compounds
  • Astringents
  • Chlorides
  • Gels
  • Aluminum Chloride
  • Salicylic Acid